Literature DB >> 32803313

Phenotypical and functional abnormalities of circulating neutrophils in patients with β-thalassemia.

Brigitta Buttari1, Elisabetta Profumo1, Patrizia Caprari2, Sara Massimi3, Francesco Sorrentino4, Laura Maffei4, Marco Gabbianelli1, Rachele Riganò1.   

Abstract

β-Thalassemia is an inherited single gene disorder related to reduced synthesis of the β-globin chain of hemoglobin. Patients with β-thalassemia present variable clinical severity ranging from asymptomatic trait to severe transfusion-dependent anemia and multiple organs complications. Moreover, multiple immune abnormalities are a major concern in β-thalassemia patients. Aberrant neutrophil effector function plays a pivotal role in infection susceptibility in these patients. In severe and persistent inflammation, immature neutrophils are released from the bone marrow and are functionally different compared with mature ones. Despite some abnormalities reported for thalassemia patient's immune system, few data exist on the characterization of human neutrophils in β-thalassemia. The aim of this study was to investigate the phenotype and function of circulating neutrophil subsets in patients with β-thalassemia major and with β-thalassemia intermedia divided in transfusion-dependent and non-transfusion-dependent. By the use of immunochemical and cytofluorimetric analyses, we observed that patients' CD16+ neutrophils exhibit abnormalities in their phenotype and functions and the abnormalities vary according to the clinical form of the disease and to the neutrophil subset (CD16bright and CD16dim). Abnormalities include altered surface expression of the innate immune receptor CD45, Toll-like receptor 4, and CD32, reduced ability to produce an oxidative burst, and elevated levels of membrane lipid peroxidation, especially in patients with a more severe form of the disease. Overall, our results indicating the occurrence of an immuno-senescent phenotype on circulating neutrophils from thalassemia patients suggest the usefulness of neutrophil feature assessment as a tool for better clinical management of β-thalassemia.

Entities:  

Keywords:  Immuno-senescence; Neutrophils; Oxidative biomarkers; Thalassemia; Transfusion

Mesh:

Substances:

Year:  2020        PMID: 32803313     DOI: 10.1007/s00277-020-04213-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  39 in total

Review 1.  Infections and thalassaemia.

Authors:  Sandro Vento; Francesca Cainelli; Francesco Cesario
Journal:  Lancet Infect Dis       Date:  2006-04       Impact factor: 25.071

Review 2.  Optimal management of β thalassaemia intermedia.

Authors:  Ali T Taher; Khaled M Musallam; Maria Domenica Cappellini; David J Weatherall
Journal:  Br J Haematol       Date:  2011-01-20       Impact factor: 6.998

Review 3.  Thalassaemia.

Authors:  Ali T Taher; David J Weatherall; Maria Domenica Cappellini
Journal:  Lancet       Date:  2017-07-31       Impact factor: 79.321

4.  Immune profile alterations in thalassaemic patients.

Authors:  L Quintiliani; A Mastromonaco; E Giuliani; A Buzzonetti; P Sisti; M Guglielmetti; P Iudicone; E Greca; A M Damiano; A M Ciancamerla
Journal:  Boll Ist Sieroter Milan       Date:  1983

5.  Severe infections in thalassaemic patients: prevalence and predisposing factors.

Authors:  Galia Rahav; Vania Volach; Mervyn Shapiro; Deborah Rund; Eliezer A Rachmilewitz; Ada Goldfarb
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

Review 6.  Interaction of Transfusion and Iron Chelation in Thalassemias.

Authors:  John B Porter; Maciej W Garbowski
Journal:  Hematol Oncol Clin North Am       Date:  2018-04       Impact factor: 3.722

7.  Monocyte-macrophage (M-M) functions in asymptomatic hemophiliacs and supertransfused thalassemics.

Authors:  M S Sternbach; C Tsoukas; M Paquin; N Lajeunesse; H Strawczynski
Journal:  Clin Invest Med       Date:  1987-07       Impact factor: 0.825

8.  Altered T and B lymphocytes in multitransfused patients of thalassemia major.

Authors:  D Dua; M Choudhury; K Prakash
Journal:  Indian Pediatr       Date:  1993-07       Impact factor: 1.411

9.  Survival and disease complications in thalassemia major.

Authors:  C Borgna-Pignatti; S Rugolotto; P De Stefano; A Piga; F Di Gregorio; M R Gamberini; V Sabato; C Melevendi; M D Cappellini; G Verlato
Journal:  Ann N Y Acad Sci       Date:  1998-06-30       Impact factor: 5.691

10.  Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.

Authors:  Bianca Maria Ricerca; Arturo Di Girolamo; Deborah Rund
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-28       Impact factor: 2.576

View more
  1 in total

Review 1.  New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

Authors:  Mara Carsote; Cristina Vasiliu; Alexandra Ioana Trandafir; Simona Elena Albu; Mihai-Cristian Dumitrascu; Adelina Popa; Claudia Mehedintu; Razvan-Cosmin Petca; Aida Petca; Florica Sandru
Journal:  Diagnostics (Basel)       Date:  2022-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.